Search
Products
Community
Markets
News
Brokers
More
EN
Black Friday sale
Up to 70% OFF
Community
/
Ideas
/
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic
Sanofi
Long
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic
By RocketTickers
Follow
Follow
Mar 11, 2019
0
Mar 11, 2019
REGN,SNY: Sanofi
2019-03-11 15:45:00
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents - PR Newswire
Beyond Technical Analysis
RocketTickers
Follow
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the
Terms of Use
.